Stock Price & Analysis

Analysis and Insights

To determine whether it’s a good time to buy or sell IDXX stock, we need to look at both technical and fundamental factors.

Fundamental Analysis:

IDEXX Laboratories (IDXX) has shown strong financial performance, with Q4 2024 revenue of $954.3 million and EPS of $2.62, exceeding Wall Street expectations. The company's Companion Animal Group (CAG) drove growth, contributing $870.5 million, a 6% year-over-year increase. IDXX also provided a positive outlook for fiscal 2025, expecting revenue growth of 4% to 7% and EPS growth of 10% to 15%.

Valuation Analysis:

IDXX is currently trading below its mean price target of $518.50, suggesting potential upside. The stock has a "Moderate Buy" consensus rating from analysts, indicating cautious optimism.

Technical Analysis:

IDXX has been trading below its 50-day and 200-day moving averages since mid-June 2024, indicating a bearish trend. However, the stock saw an 11.1% increase following strong Q4 earnings, showing positive momentum.

Market Outlook:

IDXX is part of the ProShares Ultra QQQ ETF (QLD), which has an implied analyst target price of $113.47, indicating a 21.33% upside. This reflects optimism about IDXX's future performance.

Conclusion:

Given the strong earnings, positive analyst sentiment, and potential upside, IDXX stock is a buy. However, this analysis does not constitute financial advice, and you should do your own research or consult a financial advisor.

IDXX stock is predicted to reach $566 by 2025, driven by strong Q4 earnings with revenue of $954.3 million and EPS of $2.62, exceeding expectations. Analysts have a mean price target of $518.50, with a potential upside of 22.1%.

The S1 support level for IDXX Stock is $413.26 ,The R1 resistant level for IDXX Stock is $427.68.

As of the end of day on 2025-04-01, the price of IDXX Stock was $419.12.

The target price for IDXX Stock according to analyst rating is 517.14, with the highest price target at 550.00 and the lowest at 450.00. Analysts have a Moderate Buy rating on IDXX Stock overall.

The market cap of IDXX is $33.9B.

IDXX appears overvalued based on high valuation metrics and mixed analyst sentiment. Its PE ratio of 48.29 and EV/EBITDA of 28.52 indicate a premium valuation. While revenue has grown steadily, net income has been inconsistent. Analysts have mixed opinions, with some raising targets but others maintaining a cautious stance. The stock's current price nears the higher end of analyst targets, and technical indicators suggest potential resistance. Considering market conditions and valuation, IDXX may be overvalued.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.

IDXX stock is predicted to reach $600 by 2030, driven by strong financial performance and product innovation. The company's Q4 2024 earnings exceeded expectations with revenue of $954.3 million and EPS of $2.62, supported by growth in its Companion Animal Group. Analysts maintain a "Moderate Buy" consensus with a mean price target of $518.50, indicating confidence in its long-term potential.

IDXX has a total of 11000 employees.